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ABSTRACT
Patients with pancreatic ductal adenocarcinoma (PC) have a poor prognosis due 
to metastases and chemoresistance. PC is characterized by extensive fibrosis, which 
creates a hypoxic microenvironment, and leads to increased chemoresistance and 
intracellular oxidative stress. Thus, proteins that protect against oxidative stress are 
potential therapeutic targets for PC. A key protein that maintains genomic integrity 
against oxidative damage is MutY-Homolog (MYH). No prior studies have investigated 
the function of MYH in PC cells. Using siRNA, we showed that knockdown of MYH in PC 
cells 1) reduced PC cell proliferation and increased apoptosis; 2) further decreased PC 
cell growth in the presence of oxidative stress and chemotherapy agents (gemcitabine, 
paclitaxel and vincristine); 3) reduced PC cell metastatic potential; and 4) decreased 
PC tumor growth in a subcutaneous mouse model in vivo. The results from this study 
suggest MYH may be a novel therapeutic target for PC that could potentially improve 
patient outcome by reducing PC cell survival, increasing the efficacy of existing drugs 
and reducing metastatic spread.
INTRODUCTION
Pancreatic ductal adenocarcinoma [herein referred 
to as pancreatic cancer (PC)] is a highly metastatic and 
chemoresistant disease with a dismal 5-year survival rate 
at 7% [1, 2]. Our current best treatment is surgery, but 
< 15% of patients present with resectable PC [3, 4]. For 
the remainder of patients, our current chemotherapeutic 
strategies only prolong median survival by 8-16 weeks 
[5]. Part of the reason PC treatments often fail, is the 
highly fibrotic PC microenvironment [6, 7]. Fibrosis 
distorts the tumor vasculature creating a hypoxic and 
nutrient-deprived environment [6, 7]. Hypoxia and 
nutrient-deprivation drive the Warburg effect (a switch 
from oxidative to glycolytic energy production) and the 
transition of cancer cells from an epithelial phenotype, 
to a more metastatic and chemoresistant mesenchymal 
phenotype [8–11]. These features also impose additional 
oxidative stress on PC cells. This is because hypoxia 
induces the release of reactive oxygen species (ROS) from 
mitochondria, initiating a signaling cascade to facilitate 
cell survival [12]. In addition, the Warburg effect results 
in loss of potent anti-oxidant intermediates, reducing the 
ability of cancer cells to mop-up ROS [9]. 
ROS are mutagenic as they are highly reactive 
with DNA bases. Intracellular ROS are generated 
by normal cell metabolism, but can be increased by 
microenvironmental pressures (as described above) 
and chemotherapeutics [8–11, 13]. If left ignored, DNA 
damage induced by oxidative stress can accumulate 
to a point that it induces cell death, either by inducing 
irreparable DNA double strand breaks or by accumulating 
      Research Paper
Oncotarget9217www.impactjournals.com/oncotarget
excessive DNA mutation that compromises the basic 
functions of the cell [14]. Proteins involved in cellular 
responses that protect cells from oxidative stress are 
increasingly being recognized as potential therapeutic 
targets for cancer. For example, Kiebala et al. [15] 
demonstrated that dual inhibition of thioredoxin and 
glutathione antioxidant systems synergistically reduced 
malignant B cell viability but did not affect normal B cells, 
in vitro. Sulfasalazine is a drug that reduces glutathione 
production and cellular protection from oxidative stress, 
and has been shown to reduce pancreatic cancer cell 
viability [16]. MTH1 protects the genome from oxidative 
DNA damage by sanitising dNTP pools of oxidized DNA 
bases, preventing their incorporation into DNA [17, 18]. 
Inhibitors of MTH1 have been shown to be effective 
at killing cancer cells (including PC cells) in vitro and 
in vivo [17, 18]. The base excision repair (BER) pathway is 
a major player in cellular protection from oxidative stress 
and has been identified as a key regulator of resistance to 
a variety of chemotherapeutics [19, 20]. Targeting BER 
proteins involved in oxidative DNA damage repair may 
thus chemosensitize cancer cells and reduce their survival 
in a ROS-promoting microenvironment.
The most common form of oxidative DNA damage 
is the oxidation of guanines (G) to 8-oxo-guanine 
(8-oxo-G) in G:C base pairs. If the 8-oxo-G is not 
removed, replication machinery can mis-insert adenine (A) 
opposite 8-oxo-G, which becomes a permanent mutation 
(G:C to T:A) in subsequent rounds of replication [21]. 
The BER proteins OGG1 and MYH play major roles in 
repairing this damage. OGG1 directly removes 8-oxo-G, 
while MYH prevents this DNA damage from becoming a 
permanent mutation, by removing A incorrectly inserted 
opposite G [22]. MYH also plays a critical role in co-
ordinating other BER proteins at these DNA damage 
sites including OGG1 to ensure repair is carried out 
correctly [23, 24]. MYH has been shown to interact with 
components of the mismatch repair (MMR) pathway, 
a DNA repair pathway that recognises DNA backbones 
deformities due to base mismatches [25]. Interactions 
with MMR proteins have been shown to enhance MYH 
activity rather than compete with it, indicating MYH plays 
a central role in repair of oxidative DNA damage [25].
Given the PC microenvironment promotes oxidative 
stress and that MYH plays an important role in protecting 
cells from oxidative DNA damage, we hypothesized that 
MYH may be a therapeutic target for PC. Despite its 
critical role in oxidative DNA damage repair, MYH has not 
been studied as a therapeutic target in any cancer. We show 
that MYH silencing using siRNA reduces PC cell survival 
and metastatic potential, and increases chemosensitivity 
in vitro. In addition, therapeutic inhibition of MYH using 
a nanoparticle siRNA approach significantly decreased PC 
tumor growth in vivo. The results from this work identify 
MYH as a novel therapeutic target for PC.
RESULTS
Expression of MYH in PC cells and knockdown 
of MYH using siRNA
To assess the expression of MYH in PC cells, we 
first analyzed MYH protein levels in human PC tissue 
specimens by immunohistochemistry. We observed 
abundant MYH in PC tumour tissue but not in control 
pancreatic tissue (normal pancreas or benign conditions; 
16/20 pancreatic cancer tissue microarray specimens 
showed upregulation of MYH relative to the normal/
benign pancreas cohort; Figure 1A). MYH was found to 
be highly expressed in PC cells (Figure 1Bii) with variable 
nuclear staining (Figure 1Bii). Variations in nuclear 
localization were most likely linked to cell cycle, as 
MYH localization has been shown to be primarily nuclear 
during S-phase and diffuse throughout other phases [26]. 
In contrast, MYH expression was low in normal acinar 
cells (enzyme-secreting cells of the pancreas) adjacent 
to the tumor (Figure 1Biii). We also investigated MYH 
expression in protein extracts from normal human 
pancreatic ductal epithelial cells (HPDE cells) and the 
PC cell lines MiaPaCa-2, HPAFII, Panc-1 and AsPC-1 
(MiaPaCa-2, Panc-1: primary tumor-derived; HPAFII and 
AsPC-1: metastases-derived). Abundant MYH protein 
was detected in all lines including HPDE cells, though 
levels were variable between PC cells (Figure 1C). This 
variation was important as it represents the heterogenous 
nature of pancreatic cancer [27]. It should be noted that 
while primary HPDE cells represent “normal” pancreatic 
cells, these are cultured on plastic and are constantly 
proliferating unlike the situation in vivo. Nevertheless, 
it is not surprising that MYH would be expressed in 
non-cancerous cells, as it plays a role in protecting the 
mammalian genome against basal oxidative DNA damage 
(see introduction). We chose to pursue our experiments 
in MiaPaCa-2 and AsPC-1 cell lines as these represented 
primary and metastatic locations as well as varying 
expression of MYH.
We next established whether MYH could be silenced 
in PC cells using siRNA. MiaPaCa-2 and AsPC-1 cells 
were transfected with either control non-silencing siRNA 
(ns-siRNA) or siRNA against MYH (MYH-siRNA). At 
96 h post-transfection, we observed > 80% knockdown at both 
the mRNA and protein level in both cell lines (MiaPaCa-2 
= 83.3 ± 2.5% protein knockdown and 73.4 ± 0.8% RNA 
knockdown relative to ns-siRNA, p < 0.001; AsPC-1, 
86.2 ± 3.5% protein knock-down and 73.6 ± 2.4% RNA 
knock-down relative to ns-siRNA, p < 0.01; Figure 2). To 
determine if knockdown of MYH resulted in a compensatory 
increase in OGG1, we also measured OGG1 protein 
expression in PC cells following treatment with MYH-siRNA. 
MYH knockdown had no effect on OGG1 protein expression 
in MiaPaCa-2 and AsPC-1 (Supplementary Figure S1).
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MYH knockdown reduces PC cell proliferation 
and sensitizes them to oxidative stress
We then assessed the effect of MYH knockdown 
on PC cell proliferation under normal culture conditions. 
MiaPaCa-2 and AsPC-1 cells were transfected with 
ns-siRNA or MYH-siRNA. Proliferation was measured 
96 h post-transfection, by trypan blue staining and live 
cell count on a BioRAD automated cell counter. MYH 
knockdown significantly reduced the proliferation of 
both PC lines 96h post-transfection, relative to ns-siRNA 
controls (MiaPaCa-2 = 54.8 ± 6.5% reduction relative to 
ns-siRNA, p < 0.05; AsPC-1 = 39.21 ± 1.3% reduction 
relative to ns-siRNA, p < 0.05; Figure 3A–3B). Notably, 
this effect was maintained when the experiment was 
repeated in the presence of hypoxia (48 h), a prominent 
feature of the PC microenvironment (Supplementary 
Figure S2A–S2B). 
To determine if MYH was important in protecting 
PC cells from oxidative stress, we measured the effect of 
MYH knockdown on PC cell proliferation in the presence 
of the oxidative stress agent t-butyl hydroperoxide 
(t-BHP). MiaPaCa-2 and AsPC-1 cells were transfected 
with ns-siRNA or MYH-siRNA. 48 h post-transfection, 
either normal medium (control) or t-BHP was added 
to the cultures. Addition of t-BHP to culture medium 
significantly increased intracellular oxidative stress in 
PC cells, as assessed by MitoSOXTM staining (fluoresces 
in response to oxidation by superoxide in mitochondria; 
increased intracellular oxidative stress results in increased 
fluorescence) and flow cytometry (Figure 3C–3D). Cells 
were cultured for a further 48 h before proliferation was 
measured by trypan blue staining and live cell count. We 
found that MYH knockdown was able to significantly 
increase the sensitivity of both PC lines to oxidative stress 
(Figure 3A–3B). 
Figure 1: Expression of MYH in human pancreatic adenocarcinoma tissue and cell lines. (A) Panels show control tissue 
(normal pancreas or benign pancreatic conditions) or pancreatic cancer tissue stained with MYH antibody (brown). Closer views of normal 
acinar cells (top panels) or pancreatic cancer cells (bottom panels) are shown in insets. (B) Magnified field of view showing human 
pancreatic cancer tissue stained with either isotype control antibody (i) or MYH antibody (ii-iii). The isotype control was negative and 
tumor elements had strong immunoreactivity for MYH. Labels demonstrate cytoplasmic+nuclear staining (*) versus cytoplasmic only 
staining (#). Panel (iii) demonstrates low MYH staining in normal acinar cells. (C) Western blot analysis of MYH in protein extracts from 
normal human pancreatic ductal epithelial cells (HPDE cells) and pancreatic cancer cell lines. GAPDH was used as a loading control.
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Silencing MYH in PC cells modulates cell cycle 
and induces apoptosis 
We next investigated the effect of MYH knockdown 
on (i) cell cycle and (ii) apoptosis in PC cells. MiaPaCa-2 
and AsPC-1 cells were transfected with ns-siRNA or MYH-
siRNA. (i) 48 h post-transfection, MiaPaCa-2 cells were 
treated with t-BHP for a further 48 h. Cells were then stained 
with propidium iodide and cell cycle distribution determined 
by flow cytometry. In MiaPaCa-2, MYH knockdown alone 
significantly reduced the proportion of cells in G1 phase 
(pre-replication) and increased the proportion of cells in 
S (replication) and G2/M phase (post-replication/mitosis 
phase; Figure 4A; Supplementary Figure S3A). Moreover, 
t-BHP treatment further increased the proportion of cells 
in G2/M phase, while reducing cells in G1- and S-phase 
(Figure 4A; Supplementary Figure S3A). In contrast, 
silencing MYH in AsPC-1 increased cells in G1-phase 
(Figure 4B; Supplementary Figure S3B). Treatment of AsPC-
1 with t-BHP caused G2/M arrest as observed in MiaPaCa-2 
(Figure 4B; Supplementary Figure S3B). However, 
MYH knockdown in AsPC-1 inhibited t-BHP-induced 
G2/M arrest (Figure 4B; Supplementary Figure S3B); 
(ii) 96 h post-transfection, apoptosis was measured in 
MiaPaCa-2 and AsPC-1 cells by AnnexinV/7AAD staining 
and flow cytometry. MYH knockdown significantly 
increased apoptosis in both PC cell lines (MiaPaCa-2: 
87.4 ± 21% increase relative to ns-siRNA controls, 
p < 0.05; AsPC-1: 58.7 ± 11.2% increase relative to ns-
siRNA controls, p < 0.001; Figure 4C–4D). The results 
indicating that, at least in part, the anti-proliferative effect 
of MYH-siRNA was via induction of apoptosis, albeit by 
potentially different pathways as suggested by cell cycle data.
Silencing MYH in PC cells reduces clonogenicity 
and increases chemosensitivity
Chemotherapeutics are capable of causing oxidative 
stress in addition to their primary function [13]. We next 
measured the effect of silencing MYH in PC cells on 
chemosensitivity to the anti-metabolite gemcitabine and 
the microtubule binding agents paclitaxel and vincristine, 
using a clonogenic assay. First, we observed that MYH 
knockdown alone significantly reduced colony numbers 
Figure 2: Knockdown of MYH in pancreatic cancer cells. RNA and protein was extracted from cells 96 h after transfection 
with control siRNA (ns-siRNA) or MYH-siRNA. (A–B) qPCR analysis of MYH knockdown in RNA extracts from (A) MiaPaCa-2 and 
(B) AsPC-1. Samples were standardised to 18S RNA. (C–D) Western blot analysis of MYH silencing in protein extracts from (C) MiaPaCa-2 
and (D) AsPC-1 cells. GAPDH was used as a loading control. Graphs show densitometry of Western blots for MYH (representative Western 
blots shown in top panel). Asterisks indicate significance (**p ≤ 0.01, ***p ≤ 0.001; n = 3).
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in MiaPaCa-2 and AsPC-1 (Figure 5). Importantly, MYH 
knockdown potently increased the chemosensitivity of 
both cell lines to paclitaxel and vincristine (Figure 5B–5F) 
and of MiaPaCa-2 to gemcitabine (Figure 5A), relative to 
controls. MYH knockdown had no effect on gemcitabine 
sensitivity in AsPC-1 cells (Figure 5D).
Silencing MYH in PC cells reduces their 
metastatic potential
To determine if MYH also controlled the metastatic 
potential of PC cells, we measured the effect of MYH 
knockdown on anchorage-independent survival using (i) a 
soft-agar assay and (ii) an anoikis (anchorage-independent 
apoptosis) assay. (i) PC cells were transfected with 
ns-siRNA or MYH-siRNA and seeded into soft-agar. 3D 
colonies (> 50 cells) were allowed to form, and were then 
stained with MTT reagent and counted. MYH knockdown 
significantly reduced colony number of both PC cell 
lines, relative to ns-siRNA controls (MiaPaCa-2: 34.3 ± 
8% reduction in colony number; AsPC-1: 65.4 ± 14.1% 
reduction in colony number; p < 0.05; Figure 6A–6B). 
(ii) MiaPaCa-2 cells were transfected with ns-siRNA or 
MYH-siRNA, then cultured for 48 h in polyHEMA-coated 
plates (in suspension). Apoptosis was then measured 
by AnnexinV/7AAD staining and flow cytometry. We 
found that MYH knockdown significantly increased 
anoikis in MiaPaCa-2 cells, relative to ns-siRNA controls 
(67.9 ± 5.8% increase relative to ns-siRNA controls, 
p < 0.01; Figure 6C). We then performed a complimentary 
assay suitable for measuring anchorage-independent survival 
in MiaPaCa-2 and AsPC-1 cells under the same conditions, 
using cell counting kit 8 (Dojindo). This colorimetric 
assay is a measure of the number of live cells in a culture. 
Consistent with anoikis assay results, MYH knockdown in 
MiaPaCa-2 reduces the number of live cells under anchorage 
independent growth (Figure 6D). However, no effect was 
observed in AsPC-1 cells (Figure 6E), suggesting the effect 
of MYH knockdown on PC cell anoikis is cell line –specific.
MYH knockdown reduces subcutaneous PC 
tumor growth
We tested whether the effects of MYH silencing 
in PC cells would translate to an in vivo setting, using a 
subcutaneous mouse model of PC (MiaPaCa-2). Control- or 
Figure 3: The effect of MYH knockdown on pancreatic cancer cell proliferation and sensitivity to oxidative stress. 
(A–B) Proliferation assay of (A) MiaPaCa-2 cells and (B) AsPC-1 cells transfected with control siRNA (ns-siRNA) or MYH-siRNA. 
48 h post-transfection, cells were cultured ± t-butyl hydroperxoide (t-BHP) for a further 48 h. Cells were then lifted and live cells counted 
on an automated BioRAD cell counter (trypan blue staining). Bars represent the total live cell count as a fraction of ns-siRNA control 
(± s.e.m.). (C–D) MitoSOXTM assay of oxidative stress in (C) MiaPaCa-2 and (D) AsPC-1 cells after stimulation with 37 µM or 148 µM 
t-BHP, respectively. Asterisks indicate significance relative to ns-siRNA controls (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; n ≥ 3). 
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MYH-siRNA was delivered intratumorally every 48 h 
using in vivo JetPEI® (Polyplus), a nanoparticle designed 
for in vivo siRNA delivery and currently in clinical trial 
for the treatment of PC (clinicaltrials.gov Identifier: 
NCT01274455). Tumor volume was calculated every 
48 h by calliper measurement. Tumors were harvested 
24 h after the final injection for immunohistochemical 
analysis of MYH knockdown. We confirmed MYH 
knockdown in PC tumors (Figure 7A) and observed that 
MYH knockdown significantly reduced tumor growth, 
relative to controls (Figure 7B–7D).
DISCUSSION
PC is a highly lethal disease that urgently requires 
more effective therapeutic treatments. There is strong 
rationale for targeting proteins that protect cells from 
oxidative stress in solid tumors like PC, as the hypoxic 
tumor microenvironment, the altered metabolism of tumor 
cells and chemotherapeutic treatments can all increase 
intracellular oxidative stress [6, 7, 9, 12, 13]. MYH is 
a key DNA repair protein involved in repairing DNA 
damage caused by oxidative stress [22]. Few studies have 
Figure 4: MYH knockdown alters cell cycle and induces apoptosis in pancreatic cancer cells. (A–B) Cell cycle: (A) 
MiaPaCa-2 cells or (B) AsPC-1 cells were transfected with ns-siRNA or MYH-siRNA. 48 h post-transfection, cells were cultured in 
t-butyl hydroperoxide (t-BHP). 48 h later, cells were stained with PI and DNA content measured by flow cytometry. (C–D) Apoptosis: 
(C) MiaPaCa-2 or (D) AsPC-1 cells were transfected with ns-siRNA or MYH-siRNA. Apoptosis was determined 96 h post-transfection, 
by AnnexinV + 7AAD staining and flow cytometry. Bars represent the fraction of total MiaPaCa-2 or AsPC-1 cells that were apoptotic 
(± s.e.m.). Asterisks indicate significance relative to ns-siRNA controls (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n ≥ 3).
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investigated the functional role of MYH in cancer cells 
and are conflicting on whether inhibition of MYH protects 
cancer cells or compromises their survival in oxidative 
stress. For example, Hwang et al. [28] demonstrated 
that MYH knockdown in HeLa cells sensitizes them 
to oxidative stress, whereas a more recent study in 
multiple cancer cell lines by Oka et al. [29] showed that 
MYH knockdown improved cancer cell survival in p53-
proficient cells. In this manuscript, for the first time, 
we identified MYH as an important survival factor in 
PC cells (p53-mutated). Using RNAi, we showed that 
MYH knockdown in PC cells significantly reduced their 
tumorigenic and metastatic potential and increased their 
sensitivity to a broad range of chemotherapeutic drugs.
We started our investigation by examining MYH 
protein levels in human PC tissue specimens. Current 
International Cancer Genome Consortium databases show 
that mutations of MYH and alterations in mRNA levels 
occur in < 4% of patients with PC (based on Californian 
and Australian PC databases–International Cancer 
Genome Consortium). However, MYH protein levels 
have never been investigated in PC. We found that MYH 
was upregulated in human PC tissue, relative to normal/
benign pancreas conditions. When we examined MYH 
protein levels in HPDE cells and different PC cell lines, 
we observed significant variation in expression, reflecting 
the heterogeneity of PC. The high level of MYH in HPDE 
cells was somewhat unexpected given the low level of 
Figure 5: MYH knockdown reduces pancreatic cancer cell clonogenicity and increases chemosensitivity. Bars represent 
the number of MiaPaCa-2 colonies (mean+s.e.m. as a % of control siRNA (ns-siRNA) 0 nM drug) that formed from low density seeding 
following transfection with ns-siRNA or MYH-siRNA and 72 h culture in gemcitabine (A), paclitaxel (B) or vincristine (C). (D–F) as per 
A–C, except experiments were carried out with AsPC-1 cells. Asterisks indicate significance relative to the 0nM control for the same siRNA 
(*p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001; n ≥ 4). Hashes indicate significance relative to the ns-siRNA control of the same drug dose 
(#p ≤ 0.05, ##p ≤ 0.01, ###p ≤ 0.001, ####p ≤ 0.0001; n ≥ 4).
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staining in human control pancreas tissue. However, 
rapidly proliferating HPDE cells cultured on plastic do 
not necessarily reflect the status of these cells in vivo. 
Moreover, an examination of MYH mRNA expression in 
various tissues in the body showed low MYH expression in 
normal pancreas and highest expression in the thymus [30].
To represent the clinical situation, we pursued our 
experiments in PC cells of different origins (MiaPaCa-2: 
primary tumor-derived; AsPC-1: metastatic site–derived) 
and with different levels of MYH expression (MiaPaCa-2: 
higher MYH expression; AsPC-1: lower MYH expression). 
Despite the differences in MYH expression between the 
cell lines, MYH silencing significantly decreased the 
proliferation of both MiaPaCa-2 and AsPC-1 cells in the 
absence of any additional stress. This effect was enhanced 
by the addition of t-BHP, an oxidative stress-inducing 
compound. The results suggested that MYH plays a basic 
survival function in PC cells, that is likely associated with 
its established function in maintaining genomic integrity 
in the presence of oxidative stress [28]. In contrast, 
hypoxia failed to enhance the anti-proliferative effect of 
MYH knockdown. However, it should be noted that our 
in vitro system is a model of acute hypoxia, which may 
not have the same effect as chronic hypoxia and does 
not generate additional oxidative stress (Supplementary 
Figure S2C). What this result did highlight was that the 
effect of MYH knockdown was maintained in the presence 
of a key feature of the PC microenvironment. 
Further evidence supporting MYH’s proposed 
function in PC cells came from our cell cycle analysis. 
In MiaPaCa-2 cells, MYH knockdown alone significantly 
increased accumulation of cells in replication and post-
replication phases (when DNA is most exposed to free 
radicals) while reducing the proportion of cells in G1 
Figure 6: MYH knockdown reduces pancreatic cancer cell metastatic potential. (A) MiaPaCa-2 or (B) AsPC-1 transfected 
with control siRNA (ns-siRNA) or MYH-siRNA were embedded in soft-agarose at 48 h post-transfection and allowed to form colonies. 
Bars represent the number of colonies that formed (mean+s.e.m. as a % of ns-siRNA). Asterisks indicate significance (*p ≤ 0.05, 
**p ≤ 0.01; n ≥ 3). (C) MiaPaCa-2 cells were transfected with ns-siRNA or MYH-siRNA and 24 h post-transfection cells were cultured under 
anchorage independent conditions for a further 48 h (wells coated with Poly-HEMA). Bars represent the apoptotic fraction determined by 
AnnexinV + 7AAD staining and flow cytometry (mean + s.e.m.). Asterisks indicate significance (**p ≤ 0.01; n = 3). (D–E) MiaPaCa-2 or 
AsPC-1 cells were cultured as in C), before the number of live cells was measured using cell counting kit 8 (cck8; colorimetric assay whose 
absorbance directly correlates with live cell number). Bars represent the absorbance for each siRNA treatment (mean + s.e.m). Asterisks 
indicate significance (*p ≤ 0.05; n = 3).
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phase. The altered cell cycle may be indicative of increased 
DNA damage that now has to be repaired by less efficient 
DNA repair pathways, or that is triggering checkpoint 
arrest. Moreover, t-BHP further increased accumulation 
of cells in G2-M phase, suggesting hindered G2-M phase 
progression or arrest. In contrast, MYH knockdown in 
AsPC-1 cells increased accumulation of cells in G1-phase. 
Addition of t-BHP hindered G2-M phase progression as 
in MiaPaCa-2 cells. However, unlike MiaPaCa-2, MYH 
knockdown in AsPC-1 did not enhance G2-M phase 
arrest, but in fact reduced it. The results implied that MYH 
knockdown may have induced different mechanisms in 
each line. Based on MYH’s well-established DNA repair 
role, it is likely that MYH knockdown allowed greater 
accumulation of oxidant-induced mutation in both cell 
lines. In MiaPaCa-2, this appeared to have triggered a 
checkpoint response, whereas in AsPC-1, there may have 
been a failure to trigger a checkpoint response. Regardless 
of the mechanism, MYH knockdown in significantly 
increased apoptosis in both of the tested PC lines. The 
results suggest that MYH may be a versatile target in PC 
cells. On the one hand, it can hinder cell cycle progression, 
potentially leading to or accompanying apoptosis, while 
on the other, it can suppress cell cycle responses to DNA 
damage, leading to unchecked accumulation of DNA 
damage and ultimately apoptosis. Indeed, MYH has 
been shown to control cell cycle checkpoint proteins in 
response to DNA damage through intermediate signalling 
proteins [31, 32]. Differences in these proteins between 
different PC cell lines may dictate the pathway by which 
MYH knockdown ultimate leads to cell death.
Chemotherapeutic agents are also known to induce 
oxidative stress [13]. We investigated whether MYH 
silencing could increase the sensitivity of PC cells to the 
Figure 7: Silencing MYH in pancreatic cancer cells reduces subcutaneous tumor growth. (A) Immunohistochemistry for MYH 
in subcutaneous pancreatic (MiaPaCa-2) tumor sections treated with control siRNA or MYH-siRNA. (B) Representative photomicrographs 
of subcutaneous tumors treated with control siRNA or MYH-siRNA. (C) Growth curves showing tumor volume, over the course of JetPEI® 
+ control siRNA or MYH-siRNA treatments (mean ± s.e.m.). (D) Tumor volumes, as a fraction of starting volume, calculated from ex vivo 
measurements at endpoint (excised tumors). Asterisks indicate significance (*p ≤ 0.05; n = 4 for control siRNA and n = 6 for MYH-siRNA). 
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first-line PC treatments gemcitabine (anti-metabolite) 
and paclitaxel (tubulin stabilizer) and to an additional 
tubulin binding agent, vincristine (tubulin destabilizer), 
using a clonogenic assay. Gemcitabine and paclitaxel 
were chosen for their direct clinical relevance, as first-
line treatments for pancreatic cancer. Vincristine was 
included as an additional structurally and functionally 
distinct chemotherapeutic. This was to help discern if 
the effects observed with paclitaxel were drug-specific. 
MYH knockdown alone was able to significantly reduce 
colony formation in both PC lines, re-iterating MYH’s 
basic survival function in these cells. MYH knockdown 
also increased the chemosensitivity of the tested lines to 
tubulin binding agents (paclitaxel and vincristine) and 
of MiaPaCa-2 to the anti-metabolite gemcitabine. The 
results suggest that MYH inhibition could increase the 
efficacy of a broad range of chemotherapeutics. However, 
the cell-specific sensitization of MiaPaCa-2 cells to 
gemcitabine also suggests that MYH may be playing 
roles beyond its glycosylase activity, which may vary 
between cells depending on additional proteins it interacts 
with. In addition, tubulin binding agents and nucleotide/
nucleoside analogs generate relatively low levels of 
oxidative stress [13], supporting the proposition that the 
observed chemosensitization effects may also be due to 
other functions of MYH. 
PC is a highly metastatic disease, and any effective 
therapies against this cancer need to target the metastatic 
process. MYH has never been shown to be involved in 
any aspect of the metastatic process. However, we found 
that MYH knockdown significantly reduced anchorage-
independent growth of PC cells. In MiaPaCa-2 cells, 
this effect was a result of increased induction of anoikis 
(anchorage-independent apoptosis), which is resisted by 
metastatic cancer cells [33]. However, in AsPC-1 we did 
not observe increased anoikis, suggesting that these effects 
are dependent on the cell line. This does not detract from 
the fact that MYH knockdown reduced the anchorage-
independent growth of both PC lines. Our promising 
results indicate that, in addition to anti-tumorigenic effects 
and chemosensitization, MYH inhibition might inhibit the 
establishment of metastatic PC nodules in an in vivo setting.
While our in vitro assays provided strong evidence 
that MYH may be effective in a therapeutic setting, they 
lacked the complexity of an in vivo setting. We tested 
the effect of MYH-siRNA on PC tumor growth in an 
in vivo setting, using a subcutaneous PC mouse model 
and the nanoparticle JetPEI® for siRNA delivery. JetPEI® 
complexed to plasmid DNA encoding a fusion protein that 
converts gemcitabine to its toxic metabolite, is currently 
in clinical trial for PC (clinicaltrials.gov Identifier: 
NCT01274455). Consistent with our in vitro findings, 
silencing MYH in PC cells suppressed tumor growth. 
These results strengthen our proposal that MYH may be 
a therapeutic target for PC and form the foundation for 
future testing in orthotopic PC mouse models that combine 
PCs and pancreatic stellate cells (key pro-fibrogenic/pro-
tumorigenic cells) in an in vivo setting.
Any approach that systemically targets a DNA 
repair protein does carry some risks: (1) the potential for 
toxicity in normal cells of the body; (2) the potential to 
generate cancer elsewhere in the body; (3) generation of 
drug-resistant cancer cells. An approach targeting MYH 
would ideally be combined with chemotherapeutics that 
synergise with MYH, enhancing their ability to kill PC 
cells and reducing the chances of leaving resistant cancer 
cells. Off-target toxicity and mutation could also be 
minimised using a cancer cell-specific delivery method. 
This is important in the case of MYH as mutations in this 
protein are known to cause colon cancer [34]. Moreover, 
MYH knockout mice, while viable, are 1.7 times more 
likely to develop spontaneous tumours, particularly in the 
intestines [35]. On this point, siRNA therapeutics coupled 
to cancer-targeting nanoparticles represent an ideal avenue 
for targeting MYH in PC cells, while overcoming the 
current lack of pharmacological inhibitors against MYH 
[36–38].
Our novel work has identified MYH as a potential 
therapeutic target for PC that can (i) decrease PC cell 
survival, (ii) improve the efficacy of existing therapeutics, 
including first-line treatments for PC (gemcitabine/paclitaxel) 
and (iii) reduce the metastatic potential of PC cells. 
MATERIALS AND METHODS
Cell culture
Human PC cells (MiaPaCa-2, Panc-1, HPAFII and 
AsPC-1) were obtained from the American Tissue Culture 
Collection. MiaPaCa-2 cells were maintained in DMEM 
culture media, supplemented with 10% fetal bovine 
serum (FBS), 2.5% horse serum and 2 mM L-glutamine. 
Panc-1 cells were cultured in DMEM culture media, 
supplemented with 10% fetal bovine serum (FBS) and 
2 mM L-glutamine. HPAFII cells were cultured in MEM 
culture media supplemented 10% fetal bovine serum 
(FBS), 2 mM L-glutamine and 1mM sodium pyruvate. 
AsPC-1 cells were cultured in RPMI culture media 
supplemented with 10% FBS and 2 mM L-glutamine. 
All cells were grown at 37°C in a humidified incubator 
with 5% CO2, and were routinely screened and found 
to be free of mycoplasma. Purity of cell lines was 
confirmed by short tandem-repeat profiling (CellBank 
Australia). Normal Human Pancreatic Ductal Epithelial 
(HPDE) cells (a kind gift from Ming Tsao, Ontario 
Cancer Institute) were grown in Keratinocyte serum-
free (KSF) medium supplemented with 50 mg/ml bovine 
pituitary extract (BPE) and 5 ng/ml epidermal growth 
factor (EGF). 
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Immunohistochemistry of human PC tissue 
specimens
Human PC tissue specimens were collected by 
surgical removal. The use of human PC tissue sections 
was approved by the UNSW Human Research Ethics 
Committee (HCEC# HC14039). Paraffin-embedded tissue 
sections were stained with MYH antibody (1:100; Abnova) 
as previously described [39]. 3,3′ diaminobenzidine (DAB) 
was used as the substrate and sections were counterstained 
using hematoxylin. The specificity of the primary antibodies 
was confirmed by including isotype control antibodies at 
the same concentration as the primary antibodies. 
siRNA transfection
PC cells were transfected with siRNAs at a final 
concentration of 100 nM using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. 
All cells were transfected with smart pool On-Target 
Plus (Thermoscientific) siRNAs, which contained a pool 
of four different individual siRNAs that target different 
regions of the specific gene. siRNAs designed against 
MYH (Thermoscientific, Cat. L-008260-00L-020099-00) 
or non-targeting (control; Cat. D-001810-10-20) were 
used for this study. Knockdown was assessed 96h post-
transfection by qPCR and Western blot.
Quantitative real-time PCR
Total RNA was extracted from pancreatic cancer 
cells and transcribed to cDNA using a High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). 
qPCR was performed using the QuantiFast SYBR Green 
PCR kit (Qiagen) as previously described [39]. MYH 
primers were obtained from Qiagen (Cat. QT00039739; 
Quantitect Primer Assay, Qiagen). All data were 
normalized to the 18S gene (Cat. QT00199367; Quantitect 
Primer Assay, Qiagen).
Western blot analysis
Whole cell lysates were prepared and western blot 
analysis was performed using the following antibodies: 
HIF1-alpha (Becton Dickinson Bioscience), MYH 
(Abnova), OGG1 (Abcam Ltd) and GAPDH (Abcam Ltd) 
as previously described [40]. The blots were scanned using 
LAS4000 scanner and quantified using ImageQuant TL 
(GE Healthcare). 
Cell proliferation assays
For hypoxia experiments, cells were incubated in a 
hypoxic chamber (1% O2, 5% CO2, 94% N2) for the final 
48 h of the assay. Control cells were cultured under normal 
conditions (atmospheric O2). Induction of hypoxia was 
confirmed by Western blot for HIF1-alpha using whole 
cell protein extracts. For oxidative stress experiments, 
cells were cultured in the presence or absence (control) 
of 37–148 μM t-butyl hydroperoxide (t-BHP) for the final 
48 h of the assay. t-BHP concentrations were selected 
based on an ability to reduce PC cell proliferation by 
50% after 48 h and to induce intracellular oxidative stress 
(determined by MitoSOXTM assay). Cells were trypsinised 
96 h post-transfection and resuspended 1:1 in culture 
medium and trypan blue staining solution. Proliferation 
was measured by counting live cells (trypan blue negative) 
using a BioRAD automated cell counter. Alternatively, 
cells were stained for BrdU using a BrdU-APC kit (Becton 
Dickinson) according to the manufacturer’s instructions. 
BrdU incorporation was analysed by flow cytometry. 
Detection of oxidative stress
Oxidative stress was confirmed by MitoSOXTM Red 
reagent (Life technologies) staining and flow cytometry, 
according to the manufacturer’s instructions. Briefly, 
cells were incubated in t-butyl hydroperoxide for 48 h, 
with 24 h top-up, before incubation with MitoSOXTM Red 
reagent for 10 minutes. MitoSOXTM fluoresces in response 
to oxidation by superoxide in mitochondria. The amount 
of fluorescence produced is thus a measure of intracellular 
oxidative stress.  
Cytotoxic drug preparation
Gemcitabine (Hospira) was prepared at a stock 
concentration of 126.8 mM in saline. Paclitaxel 
(Calbiochem, Merck Biosciences) was prepared at a stock 
concentration of 2 mM in DMSO. Vincristine (Sigma) was 
prepared at a stock concentration of 2 mM in DMSO.
Cytotoxic drug-clonogenic assays
24 h post-siRNA transfection cytotoxic drug-
clonogenic assays were performed as previously described 
[40]. Briefly, cells were seeded at low density into 6-well 
plates (MiaPaCa-2 = 300 cells/well; AsPC-1 = 500 
cells/well). 24 h post-seeding, cells were incubated in 
gemcitabine, paclitaxel or vincristine for a total of 72 h. 
Colonies were allowed to form 7–12 days post-incubation 
in cytotoxic drugs. Colonies (≥ 50 cells) were then stained 
with crystal violet and counted.
Cell cycle analysis
48 h post-transfection with siRNA, cells were incubated 
with or without 74 µM t-BHP for a further 48 h. Cells were 
then lifted and fixed in 80% ice-cold ethanol for 30 min. 
After fixation, cells were stained with 10 µg/ml Propidium 
Iodide (PI) in staining buffer (PBS/1% TWEEN-20/4 µg/ml 
RNase-A) for 40 min at 37oC. DNA content was assessed on 
a BD FACSCanto-II flow cytometer.  
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Detection of apoptosis
PC cells were transfected with siRNA as described 
above. 96 h post-transfection, both adherent and floating 
cells were collected and cell death was measured using 
the AnnexinV-PE/7-AAD reagent (Becton Dickinson 
AnnexinV-PE/7AAD Apoptosis Kit) according to the 
manufacturer’s instructions. Samples were analysed on a 
BD FACSCanto-II flow cytometer.  
Soft-agar assay 
48 h post-transfection control cells (ns-siRNA) were 
counted and seeded at 2000 (MiaPaCa-2) OR 5000 (AsPC-1) 
cells per well. All other transfections were seeded according 
to control cell seeding volume. PC cells were seeded in 
0.33% agar in 2 × growth medium (2 × concentration of all 
supplements) on a 5% agar layer in 2 × growth medium, in 6 
well plates. Colonies (≥ 50 cells) were allowed to grow over 
2 weeks, after which plates were stained with 5mg/ml MTT 
in PBS for 30-60 minutes and visualized on an ImageQuant 
LAS4000 luminometer (GE Healthcare). Colony counting 
was carried out using the automated colony counting module 
of ImageQuant analysis software.
Anoikis assay
A stock solution of poly 2-hyroxyethyl methacrylate 
(Poly-HEMA; 120 mg/ml) was prepared in 95% ethanol 
and further diluted 1:10 in 95% ethanol prior to use. 1 ml 
of this solution was pipetted into a 6-well tissue culture 
plate and left to dry for 24 h at room temperature. Prior 
to use, wells were washed with PBS and complete cell 
culture medium. 24 h post-siRNA transfection MiaPaCa-2 
cells were seeded into the Poly-HEMA-coated wells. Cell 
death was then measured 48 h later by annexin V/7AAD 
staining as described above. Alternatively, MiaPaCa-2 
cells and AsPC-1 cells were cultured under the above 
conditions before the number of live cells were measured 
using cell counting kit 8 (Dojindo).
Subcutaneous PC mouse model
8 week old female BALB/c nude mice were used. 
All animal experiments were approved by the Animal 
Ethics committee, UNSW (ACEC 15/99B). MiaPaCa-2 
cells (4 × 106) were injected in 100 µl PBS into the right 
flank of host mice. 16 days post-implant, mice were 
injected intratumourally with 20 ug of control siRNA 
(Cat. P-002048-01, Millenium Science) or MYH-siRNA 
(5′CGG AAG AGG UGG UAU UGC A 3′) complexed at 
8:1 N/P ratio with in vivo JetPEI® (Polyplus), every 48 h 
for a total of 5 injections. Tumor volumes were calculated 
using the formula (length × width × height)/2. Mice were 
randomized based on tumor volume. Average tumor volume 
at the start of treatments was 53.9 ± 6.1 mm3. Tumors were 
measured using callipers every 48 h. Mice were sacrificed 
24 h after the final treatment and tumors were harvested for 
immunohistochemistry.
Immunohistochemistry of mouse subcutaneous 
PC tumors 
Paraformaldehyde-fixed/paraffin-embedded tissue 
sections were stained with MYH antibody (1:100, 
overnight, 4oC; Abnova) using a mouse-on mouse 
kit (Abacus ALS) according to the manufacturer’s 
instructions. 3,3′ diaminobenzidine (DAB) was used 
as the substrate and sections were counterstained using 
hematoxylin. The specificity of the primary antibodies was 
confirmed by including isotype control antibodies at the 
same concentration as the primary antibodies. 
Statistical analyses
 Data are expressed as mean ± SE and were analyzed 
using Student t-test or ANOVA followed by nonparametric 
Dunnett. Statistical analyses were performed using 
GraphPad Prism. A P value of < 0.05 was considered 
statistically significant.
Statement of significance
This study reports for the first time that silencing 
the DNA repair protein MutY-Homolog in pancreatic cells 
in vitro: 1) reduced pancreatic cancer cell proliferation/
clonogenicity and increased apoptosis; 2) significantly 
sensitized pancreatic cancer cells to a broad range 
of chemotherapy drugs; and 3) decreased pancreatic 
cancer cell metastatic potential. Importantly, therapeutic 
administration of MYH-siRNA intratumorally using a 
clinically relevant nanoparticle demonstrated reduced 
pancreatic tumor growth in vivo.
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